20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Big Pharma Eli Lilly And Co (NYSE:LLY) has agreed to acquire Boston biotech Akouos Inc (NASDAQ:AKUS) for a 78% premium over Monday’s closing price of $7.01.
- Lilly is paying $12.50 per share. Lilly is also shelling out one contingent value right (CVR) for up to $3 a share.
- The transaction is valued at approximately $487 million plus a contingent value right for an aggregate amount of up to approximately $610 million.
- Akouos has integrated expertise across otology, inner ear drug delivery, and adeno-associated viral gene therapies for inner ear conditions and hearing loss.
- Its lead program, AK-OTOF, attempts to treat hearing loss resulting from mutations in the otoferlin gene. AK-OTOF received its first IND clearance last month, and a Phase 1/2 trial is being planned.
- The company plans to provide an update on clinical trial initiation activities later this year.
- Other pipeline programs are designed for other genetic hearing loss conditions.
- Price Action: AKUS shares are up 87.90% at $13.17 during the premarket session on the last check Tuesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!